Kelly Paul Edward 4
4 · RELMADA THERAPEUTICS, INC. · Filed Dec 20, 2022
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2022-12-16+57,042→ 57,042 totalExercise: $3.37From: 2023-03-16Exp: 2032-12-16→ Common Stock (57,042 underlying)
Footnotes (1)
- [F1]The option vests in 16 equal quarterly installments commencing on March 16, 2023.